Gang Li

US Patent:

8039596, Oct 18, 2011

Filed:

Feb 4, 2009

Appl. No.:

12/365638

Inventors:

Steven Lee Bender - Oceanside CA, US
Gerald Fries Casperson - Ballwin MO, US
Xin Jiang - San Diego CA, US
Gang Li - San Diego CA, US
Michael Aidan North - Rancho Santa Fe CA, US
Jianying Wang - San Diego CA, US
Grant Wickman - Glasgow, GB
Peter Brams - Sacramento CA, US
Haichun Huang - Fremont CA, US
Brigitte Devaux - Palo Alto CA, US
Haibin Chen - Sunnyvale CA, US
Dawn M. Tanamachi - Milpitas CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Tim W. Sproul - Livermore CA, US
Mark Yamanaka - Pleasanton CA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ
Pfizer Inc. - New York NY

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/00

US Classification:

5303881, 53038815, 4241411, 4241421

Abstract:

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.

US Patent:

8399647, Mar 19, 2013

Filed:

Sep 20, 2011

Appl. No.:

13/237502

Inventors:

Steven L. Bender - Oceanside CA, US
Gerald F. Casperson - Ballwin MO, US
Xin Jiang - San Diego CA, US
Gang Li - San Diego CA, US
Michael A. North - Rancho Santa Fe CA, US
Jianying Wang - San Diego CA, US
Grant Wickman - Glasgow, GB
Peter Brams - Sacramento CA, US
Haichun Huang - Fremont CA, US
Brigitte Devaux - Palo Alto CA, US
Haibin Chen - Sunnyvale CA, US
Dawn M. Tanamachi - Miltpitas CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Tim W. Sproul - Livermore CA, US
Mark Yamanaka - Pleasanton CA, US

Assignee:

Pfizer Inc. - New York NY
Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07H 21/04
C12P 21/06
C12N 15/87
C12N 1/20
C12N 15/74

US Classification:

536 2353, 435 691, 435455, 4352523, 4353201

Abstract:

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.

US Patent:

20220233536, Jul 28, 2022

Filed:

May 28, 2020

Appl. No.:

17/613651

Inventors:

- San Francisco CA, US
Michael Monteith - Raleigh NC, US
Gang Li - San Diego CA, US
Susan Arangio - Los Altos CA, US
Craig Berman - Mill Valley CA, US
Michael Howland - San Francisco CA, US
Daniel Mulreany - San Francisco CA, US
Carl Dambkowski - San Mateo CA, US

International Classification:

A61K 31/506
A61P 35/04

Abstract:

Provided herein are methods of treating advanced or metastatic cholangiocarcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof, wherein the patient has progression of the cholangiocarcinoma after previous administration of another therapy.

US Patent:

20220233537, Jul 28, 2022

Filed:

May 29, 2020

Appl. No.:

17/613652

Inventors:

- San Francisco CA, US
Susan Arangio - Los Altos CA, US
Craig Berman - Mill Valley CA, US
Michael Monteith - Raleigh NC, US
Harris Soifer - San Diego CA, US
Gang Li - San Diego CA, US
Carl Dambkowski - San Mateo CA, US
Daniel Mulreany - San Francisco CA, US

International Classification:

A61K 31/506
C12Q 1/6886
C12Q 1/6874
G01N 33/574
A61K 31/7068
A61P 35/00
A61M 31/00

Abstract:

Provided herein are methods of treating an upper tract urothelial carcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof. Also provided herein are methods of treating non-muscle invasive bladder cancer by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof.

US Patent:

20190070173, Mar 7, 2019

Filed:

Aug 1, 2018

Appl. No.:

16/051815

Inventors:

- San Diego CA, US
Gang LI - San Diego CA, US
David Wesley ANDERSON - Poway CA, US
Garrett M. BRODEUR - Wynnewood PA, US
Radhika IYER - Wilmington DE, US

Assignee:

IGNYTA, INC. - San Diego CA

International Classification:

A61K 31/496
A61K 31/495
C07D 405/12
C07D 403/12
C07D 231/56
A61K 31/4745
A61K 31/4188
A61K 45/06

Abstract:

Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.

US Patent:

20170065582, Mar 9, 2017

Filed:

Nov 30, 2015

Appl. No.:

14/953969

Inventors:

- San Diego CA, US
Gang Li - San Diego CA, US
David Wesley Anderson - Poway CA, US
Garrett M. Brodeur - Wynnewood PA, US
Radhika Iyer - Wilmington DE, US

International Classification:

A61K 31/496
A61K 31/4188
A61K 31/4745

Abstract:

Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.

US Patent:

20140154268, Jun 5, 2014

Filed:

Feb 21, 2013

Appl. No.:

13/772992

Inventors:

- ST. LOUIS MO, US
- MILPITAS CA, US
XIN JIANG - SAN DIEGO CA, US
GANG LI - SAN DIEGO CA, US
MICHAEL AIDAN NORTH - RANCHO SANTA FE CA, US
JIANYING WANG - SAN DIEGO CA, US
GRANT WICKMAN - GLASGOW, GB
PETER BRAMS - SACRAMENTO CA, US
HAICHUN HUANG - FREMONT CA, US
BRIGITTE DEVAUX - PALO ALTO CA, US
HAIBIN CHEN - SUNNYVALE CA, US
DAWN M. TANAMACHI - MILPITAS CA, US
KRISTOPHER TOY - SAN JOSE CA, US
LAN YANG - MORGAN HILL CA, US
TIM W. SPROUL - LIVERMORE CA, US
MARK YAMANAKA - PLEASANTON CA, US

Assignee:

PFIZER INC. - ST. LOUIS MO
BRISTOL-MYERS SQUIBB COMPANY - MILPITAS CA

International Classification:

C07K 16/28

US Classification:

4241741, 5303873, 5303897, 536 2353, 4353201, 435 696, 435375, 435334

Abstract:

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.